Device Sacral Nerve Stimulation

Interstim

Payments companies reported to CMS as associated with Interstim. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$5.4Massociated payments (2023-2025)
11,967clinicians with associated payments
1company reporting

By year

2023 $1.8M
2024 $1.8M
2025 $1.7M

Payments reported as associated with Interstim, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Urology $1.9M
Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) $650K
Physician Assistant $464K
Colon & Rectal Surgery $363K
Family $302K
Gastroenterology (Internal Medicine) $267K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Interstim

These are the largest totals companies reported as associated with Interstim. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Howard Goldman Cleveland, OH Urology $174,123.99
Stephanie Flaspoehler Louisville, KY Adult Health (Nurse Practitioner) $124,128.89
Jannah Thompson Norton Shores, MI Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) $121,103.98
Amanda Maggart Worthington, OH Physician Assistant $118,657.85
Laura Giusto Owings Mills, MD Urology $110,232.75
Sandip Vasavada Cleveland, OH Urology $107,127.94
Cary Fishburne Charlotte, NC Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) $104,395.90
Maria Murphy Orlando, FL Colon & Rectal Surgery $62,019.68
Mariana De Jongh-Beyer Summerfield, FL Gastroenterology (Internal Medicine) $59,970.72
Keith Xavier Arlington, TX Urogynecology and Reconstructive Pelvic Surgery (Urology) $55,694.65

Prescribed Interstim?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.